Search

Author/Creator Herbst, R S

1. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. (14th May 2019)

Authors:
Hastings, K; Yu, H A; Wei, W; Sanchez-Vega, F; DeVeaux, M; Choi, J; Rizvi, H; Lisberg, A; Truini, A; Lydon, C A; Liu, Z; Henick, B S; Wurtz, A; Cai, G; Plodkowski, A J; Long, N M; Halpenny, D F; Killam, J; Oliva, I; Schultz, N
Journal:
Annals of oncology
Issue:
Volume 30:Number 8(2019)
Page Start:
1311
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study. (15th December 2019)

Authors:
Herbst, R S; de Marinis, F; Giaccone, G; Reinmuth, N; Vergnenegre, A; Barrios, C H; Morise, M; Felip, E; Andric, Z; Geater, S; Ozguroglu, M; Mocci, S; McCleland, M; Zou, W; Enquist, I; Komatsubara, K; Deng, Y; Kuriki, H; Spigel, D R; Jassem, J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042. (15th December 2019)

Authors:
Herbst, R S; Lopes, G; Kowalski, D M; Kasahara, K; Wu, Y-L; De Castro, G; Cho, B C; Turna, H Z; Cristescu, R; Aurora-Garg, D; Lunceford, J; Kobie, J; Ayers, M; Pietanza, M C; Piperdi, B; Mok, T S K
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. (17th December 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (23rd October 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. (18th January 2019)

Authors:
Herbst, R S; Baas, P; Perez-Gracia, J L; Felip, E; Kim, D -W; Han, J -Y; Molina, J R; Kim, J -H; Dubos Arvis, C; Ahn, M -J; Majem, M; Fidler, M J; Surmont, V; de Castro, G; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, E H; Lubiniecki, G M
Journal:
Annals of oncology
Issue:
Volume 30:Number 2(2019)
Page Start:
281
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (27th March 2017)

Authors:
Kadara, H; Choi, M; Zhang, J; Parra, E R; Rodriguez-Canales, J; Gaffney, S G; Zhao, Z; Behrens, C; Fujimoto, J; Chow, C; Yoo, Y; Kalhor, N; Moran, C; Rimm, D; Swisher, S; Gibbons, D L; Heymach, J; Kaftan, E; Townsend, J P; Lynch, T J
Journal:
Annals of oncology
Issue:
Volume 29:Number 4(2018)
Page Start:
1072
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (29th September 2016)

Authors:
Kadara, H; Choi, M; Zhang, J; Parra, E R; Rodriguez-Canales, J; Gaffney, S G; Zhao, Z; Behrens, C; Fujimoto, J; Chow, C; Yoo, Y; Kalhor, N; Moran, C; Rimm, D; Swisher, S; Gibbons, D L; Heymach, J; Kaftan, E; Townsend, J P; Lynch, T J
Journal:
Annals of oncology
Issue:
Volume 28:Number 1(2017)
Page Start:
75
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗